Entest Biomedical, Inc. Signs Agreement With RenovoCyte and MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) for Pilot Study Using Universal Donor Stem Cells in Treatment of Dog Osteoarthritis

Published: Oct 24, 2011

SAN DIEGO, CA--(Marketwire - October 24, 2011) - Entest BioMedical (OTCQB: ENTB) (PINKSHEETS: ENTB) announced today that, together with RenovoCyte LLC and Medistem Inc. (PINKSHEETS: MEDS), it plans to initiate a 10 dog pilot study using Canine Endometrial Regenerative Cells (CERC) in the treatment of osteoarthritis at the McDonald Animal Hospital in Santa Barbara, California. The McDonald Animal Hospital is wholly owned by Entest BioMedical.

The study will involve intravenous administration of a canine equivalent of Medistem's Endometrial Regenerative Cells (ERC). Medistem was recently granted approval from the FDA to initiate a clinical trial in human patients using its ERCs and RenovoCyte is the exclusive licensee of ERC technologies for veterinary applications.

"The Endometrial Regenerative Cells are a type of stem cell that produce substantially higher amounts of growth factors as compared to other adult stem cells, are potent at inhibiting inflammation, and can home to the site of tissue injury and exert a healing effect," said Dr. Greg McDonald, Chief Veterinarian of the McDonald Animal Hospital. "To our knowledge this is the first clinical trial of a universal donor stem cell that already is being used in human medicine, and now we have the opportunity to offer it to our clients."

Osteoarthritis is considered one of the most common causes of lameness in dogs and decreased quality of life. It is caused by a deterioration of joint cartilage, followed by pain and loss of range of motion of the joint.

"It is our commitment to provide access to the most cutting-edge veterinary medicines for hospitals under the Entest umbrella," said David Koos, Chairman and CEO of Entest. "The collaboration with RenovoCyte and Medistem allows not only access to various stem cell treatment technologies, but also veterinary stem cell banking."

"In contrast to other stem cell approaches in the area of veterinary medicine, the use of 'universal donor' cells allows for delivery of a standardized therapeutic dose to each animal. If these studies are successful, we look forward to substantially expanding the use of these cells as an 'off the shelf' stem cell product," said Dr. Shelly Zacharias, Director of Veterinary Operations at RenovoCyte.

Current stem cell therapies utilized in veterinary applications require the extraction, manipulation, and subsequent replantation of tissue from the animal being treated. The Canine Endometrial Regenerative Cell (CERC) therapy is unique in that a product is delivered to the office of the veterinarian ready for injection.

About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


Entest BioMedical Inc.

David R. Koos
Chairman & CEO

619.702.1404 Direct
619.330.2328 Fax
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine


Back to news